Magenta Therapeutics Stock News

LEXINGTON, Mass.--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. (Cyteir) (Nasdaq:CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Dr. Jeffrey S. Humphrey, MD, Chief Medical Officer of Magenta Therapeutics to its Board of Directors. Dr. Humphrey is an accomplished clinical researcher and drug developer who has shepherded numerous drugs through all phases of development from pre-IND to post-lau

Wall Street analysts expect Magenta Therapeutics, Inc. (NASDAQ:MGTA) to post ($0.36) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Magenta Therapeutics earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.47). Magenta Therapeutics posted earnings of ($0.38) per share during the same quarter last year, []

Geode Capital Management LLC boosted its holdings in shares of Magenta Therapeutics, Inc. (NASDAQ:MGTA) by 24.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 503,191 shares of the companys stock after buying an additional 99,393 shares during the period. Geode Capital Management LLC owned []

Vanguard Group Inc. lifted its stake in Magenta Therapeutics, Inc. (NASDAQ:MGTA) by 8.5% in the second quarter, Holdings Channel.com reports. The fund owned 1,543,793 shares of the companys stock after purchasing an additional 120,322 shares during the period. Vanguard Group Inc.s holdings in Magenta Therapeutics were worth $15,098,000 as of its most recent filing with []

After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.

Two new Breakout Stocks for Week 38 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges, the portfolio is u

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA).  Such investors are

New York, New York--(Newsfile Corp. - August 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA). Such inv

NEW YORK, July 21, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA). Such investors are a

Magenta Therapeutics, Inc. (MGTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising e

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more p

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more p

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more p

This clinical-stage biotech is looking to make stem cell transplantation faster, easier, and safer for both donors and patients.

Gain Therapeutics has filed to raise $40 million in a U.S. IPO.